Connor, Clark & Lunn Investment Management Ltd. Entrada Therapeutics, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 85,621 shares of TRDA stock, worth $970,085. This represents 0.01% of its overall portfolio holdings.
Number of Shares
85,621
Previous 138,605
38.23%
Holding current value
$970,085
Previous $2.22 Million
33.21%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding TRDA
# of Institutions
104Shares Held
28.9MCall Options Held
40.3KPut Options Held
4.1K-
Baker Bros. Advisors LP New York, NY4.87MShares$55.1 Million0.93% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$49.9 Million33.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$49.6 Million60.89% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$32.9 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X02.08MShares$23.6 Million0.02% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $355M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...